Tirzepatide cuts risk of diabetes by 94% in adults with ... - CNN
Aug 20, 2024 · A three-year study of tirzepatide – a medication approved in the US as Mounjaro for diabetes and Zepbound for weight loss – found that when adults who had prediabetes and obesity or overweight...
FDA says this weight loss drug shortage is over, but ... - CBS News
Oct 23, 2024 · Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing...
Mounjaro leads to significantly more weight loss than Ozempic, …
Jul 8, 2024 · People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study. Researchers from Truveta ...
Eli Lilly's tirzepatide cuts heart failure risks, company says - NBC News
Aug 1, 2024 · Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.
News Release - Eli Lilly and Company
FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes. Mounjaro delivered superior A1C reductions versus all comparators in phase 3 SURPASS clinical trials.
Mounjaro and Zepbound Are No Longer in Shortage, F.D.A. Says
Oct 3, 2024 · The Food and Drug Administration on Wednesday declared an end to the two-year shortage of tirzepatide, the substance in the popular weight-loss medication Zepbound and the diabetes drug Mounjaro....
FDA approves Eli Lilly’s diabetes drug Mounjaro for obesity ... - CNN
Nov 8, 2023 · The drug, called Mounjaro for diabetes, will be called Zepbound for weight loss, according to a news release from the FDA. Made by Eli Lilly, it’s part of a new class of drugs that includes...
FDA Says Mounjaro, Zepbound Shortage Has Ended: What to Know - Healthline
Aug 7, 2024 · Zepbound and Mounjaro have been on the Food and Drug Administration's shortage list for months. In response, manufacturer Eli Lilly spent billions ramping up production and now, according to the...
A new version of the diabetes drug Mounjaro can ... - Associated Press News
Nov 8, 2023 · A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday. The U.S. Food and Drug Administration approved Eli Lilly’s drug, named Zepbound.
News Release
It is not known if Mounjaro can be used in people who have had inflammation of the pancreas (pancreatitis). Mounjaro is not for use in people with type 1 diabetes. It is not known if Mounjaro is safe and effective for use in children under 18 years of age. Warnings - Mounjaro may cause tumors in the thyroid, including thyroid cancer. Watch for ...